In developing its pipeline of cancer therapeutics, Deciphera has applied the distinct capabilities of its kinase inhibitor platform with a strategic focus by:
- developing advanced Type 2 kinase inhibitors with demonstrated activity against many of the most clinically important kinase targets in oncology today, such as MET, TIE2, VEGFR1, VEGFR2, RAF, KIT and FMS;
- targeting kinases that play important roles in tumor communication with the surrounding tissue, known as the tumor microenvironment.
Deciphera’s pipeline of clinical candidates includes rebastinib, a TIE2 kinase inhibitor for the adjuvant treatment of solid tumors including pancreatic and breast cancers, and altiratinib (DCC-2701), a MET/TIE2/VEGFR2 kinase inhibitor for the treatment of metastatic melanoma and other invasive solid tumors. LY3009120 (DP-4978), a pan-RAF inhibitor developed in collaboration with Eli Lilly, has also entered into Phase I clinical trials in solid tumors. Preclinical pipeline assets include DCC-2618, a pan-KIT inhibitor for GIST, mast cell cancers, and other KIT-driven cancers, DCC-3014, an ultra-selective FMS inhibitor for the adjuvant treatment of solid tumor metastasis and for blocking cancer spread to bones, and DCC-2721, a selective MET inhibitor for the treatment of invasive solid tumors including gastric cancer.